Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Reduce Exposure To Mosquitoes This Summer
The Escambia County Health Department established a mosquito control program in 2008 that
generic viagra online
Glutamine Supplements Show Promise In Treating Stomach Ulcers
Nearly 20 years ago, it was discovered that bacteria known as Helicobacter pylori were responsible for stomach ulcers. Since then, antibiotics have become the primary therapy used to combat the H. pylori infection, which affects approximately six percent of the world population and is also a primary cause of stomach cancer. But today the bacteria is growing increasingly resistant to antibiotics.
News of the day
Study Led By Stanford Scientists Links Schizophrenia To Chromosome Region For The First Time
Stanford University School of Medicine scientists have played a major role in an international effort that has shown, for the first time, that modern genetic technologies can solve the riddle of how gene variations lead to schizophrenia.
Nutrition

UPMC Cardiovascular Institute Recruiting For Severe Coronary Heart Disease Study

The UPMC Cardiovascular Institute currently is enrolling participants for a Phase 2 clinical trial to examine whether administering a naturally occurring protein improves blood supply to the cardiac muscle in patients with severe coronary artery disease. The study, known as Angiogenesis for the Treatment of Coronary Heart Disease (ACORD), is a randomized, double-blind, placebo-controlled trial that compares the use of a protein at three dose levels with a placebo. The therapy is delivered to the heart muscle by threading a catheter through a small incision in the upper leg. "Other studies have hinted that this approach can reduce the severity of angina in patients who have exhausted all other treatment options," said Oscar Marroquin, M.D., director of the UPMC Center for Interventional Cardiology Research and principal investigator of the study. "It appears the protein, called FGF-1, is able to stimulate the growth of new blood vessels to get around existing blockages and improve blood flow to the heart." This trial is designed to see whether FGF-1 can help patients and, if so, how much should be given. To be eligible for the study, patients must have a history of angina or chronic chest pain that persists despite optimal drug therapy. The ACORD trial is expected to enroll 120 patients, including 10 from the UPMC Cardiovascular Institute, at 30 medical centers throughout the United States. University of Pittsburgh


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009